- Home
- IMUX
IMUX
Immunic Inc.
as 05-17-2024 4:00pm EST
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
| Founded: | N/A | Country: | United States |
| Employees: | 80 | City: | NEW YORK |
| Market Cap: | 112.1M | IPO Year: | N/A |
| Target Price: | $8.50 | AVG Volume (30 days): | 419.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.94 - $3.11 | Next Earning Date: | 05-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Stock Insider Trading Activity of Immunic Inc. (IMUX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Vitt Daniel | IMUX | President and CEO | Feb 26 '24 | Buy | $1.31 | 14,000 | $18,333.00 | 390,877 | SEC Form 4 |
Latest Immunic Inc. News
IMUX Breaking Stock News: Dive into IMUX Ticker-Specific Updates for Smart Investing
Insider Monkey
11 days ago
Immunic, Inc. (NASDAQ:IMUX) Q1 2024 Earnings Call Transcript
Simply Wall St.
11 days ago
We Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth Carefully
Associated Press Finance
12 days ago
Immunic: Q1 Earnings Snapshot
PR Newswire
12 days ago
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
PR Newswire
14 days ago
Immunic to Participate in Investor and Scientific Conferences in May
News Direct
19 days ago
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
PR Newswire
19 days ago
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
PR Newswire
20 days ago